II. Indications
- See NSAID
- FDA Approved Indications in adults
- Rheumatoid Arthritis
- Osteoarthritis
- Acuty Gouty Arthritis
- Musculoskeletal pain (Bursitis, Tendinitis)
III. Contraindications
- See NSAID
V. Medications
- Sulindac (Clinoril): 150 mg, 200 mg
VI. Dosing
- Adult
- Sulindac (Clinoril) 150 to 200 mg orally twice daily
- Maximum: 200 mg/day
- Child (not FDA approved, off-label)
- Juvenile Rheumatoid Arthritis: 4 mg/kg/day orally divided twice daily
VII. Adverse Effects
- See NSAID
-
Drug-Induced Pancreatitis
- However, Sulindac has also been investigated for the management of Chronic Pancreatitis
- Sugerman (1989) Am Surg 55(9):536-8 +PMID: 2774359 [PubMed]
- Bai (2012) BMC Gastroenterol 12:115 +PMID: 22920325 [PubMed]
- Hypersensitivity Reaction (severe, life threatening)
VIII. Safety
IX. Resources
X. References
- Hamilton (2020) Tarascon Pocket Pharmacopoeia
Images: Related links to external sites (from Bing)
Related Studies
| sulindac (on 12/21/2022 at Medicaid.Gov Survey of pharmacy drug pricing) | ||
| SULINDAC 150 MG TABLET | Generic | $0.18 each |
| SULINDAC 200 MG TABLET | Generic | $0.21 each |
Ontology: Sulindac (C0038792)
| Definition (NCI_NCI-GLOSS) | A nonsteroidal anti-inflammatory drug (NSAID) that is being studied as a treatment for cancer. |
| Definition (NCI) | A sulfinylindene derivative prodrug with potential antineoplastic activity. Converted in vivo to an active metabolite, sulindac, a nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death. (NCI04) |
| Definition (MSH) | A sulfinylindene derivative prodrug whose sulfinyl moiety is converted in vivo to an active NSAID analgesic. Specifically, the prodrug is converted by liver enzymes to a sulfide which is excreted in the bile and then reabsorbed from the intestine. This helps to maintain constant blood levels with reduced gastrointestinal side effects. |
| Definition (PDQ) | A sulfinylindene derivative prodrug with potential antineoplastic activity. Converted in vivo to an active metabolite, sulindac, a nonsteroidal anti-inflammatory drug (NSAID), blocks cyclic guanosine monophosphate-phosphodiesterase (cGMP-PDE), an enzyme that inhibits the normal apoptosis signal pathway; this inhibition permits the apoptotic signal pathway to proceed unopposed, resulting in apoptotic cell death. Check for "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41538&idtype=1" active clinical trials or "http://www.cancer.gov/Search/ClinicalTrialsLink.aspx?id=41538&idtype=1&closed=1" closed clinical trials using this agent. ("http://nciterms.nci.nih.gov:80/NCIBrowser/ConceptReport.jsp?dictionary=NCI_Thesaurus&code=C850" NCI Thesaurus) |
| Concepts | Pharmacologic Substance (T121) , Organic Chemical (T109) |
| MSH | D013467 |
| SnomedCT | 363623008, 387513000, 89505005 |
| LNC | LP18100-5, MTHU003386 |
| English | Sulindac, 1H-Indene-3-acetic acid, 5-fluoro-2-methyl-1-((4-(methylsulfinyl)phenyl)methylene)-, (Z)-, (Z)-5-fluoro-2-methyl-1-[[4-(methylsulfinyl)phenyl]methylene]-1H-indene-3-acetic acid, cis-5-fluoro-2-methyl-1-[p-(methylsulfinyl)benzylidene]indene-3-acetic acid, sulindac, Sulindac Sulfoxide, sulindac (medication), SULINDAC, Sulindac [Chemical/Ingredient], Sulindac product (substance), Sulindac product, Sulindac (product), Sulindac (substance), SULIN |
| Swedish | Sulindak |
| Czech | sulindak |
| Finnish | Sulindaakki |
| Russian | SULINDAK, СУЛИНДАК |
| Japanese | スリンダク |
| Polish | Sulindak |
| Spanish | sulindac (producto), sulindac (sustancia), sulindac, Sulindac |
| French | Sulindac |
| German | Sulindac |
| Italian | Sulindac |
| Portuguese | Sulindaco |
